MA31466B1 - Derives de benzimidazole - Google Patents

Derives de benzimidazole

Info

Publication number
MA31466B1
MA31466B1 MA32454A MA32454A MA31466B1 MA 31466 B1 MA31466 B1 MA 31466B1 MA 32454 A MA32454 A MA 32454A MA 32454 A MA32454 A MA 32454A MA 31466 B1 MA31466 B1 MA 31466B1
Authority
MA
Morocco
Prior art keywords
benzimidazole derivatives
mammals
compounds
treatment
cell growth
Prior art date
Application number
MA32454A
Other languages
Arabic (ar)
English (en)
Inventor
Christopher Scott Jones
GRECA Susan LA
Qifang Li
Michael John Munchhof
Lawrence Alan Reiter
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA31466B1 publication Critical patent/MA31466B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé de formule i (i) ou un de ses sels pharmaceutiquement acceptables, dans laquelle r1, r2, r3a, r3b, r4, r5, x, m et n sont tels que définis dans le présent document. De tels nouveaux dérivés de benzamidazole sont utiles dans le traitement de la croissance cellulaire anormale, telle que le cancer, chez les mammifères. L'invention concerne également un procédé d'utilisation de tels composés dans le traitement de la croissance cellulaire anormale chez les mammifères, notamment les humains, et des compositions pharmaceutiques qui contiennent de tels composés.
MA32454A 2007-06-29 2009-12-29 Derives de benzimidazole MA31466B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94728707P 2007-06-29 2007-06-29
US4164508P 2008-04-02 2008-04-02
PCT/IB2008/001575 WO2009004427A2 (fr) 2007-06-29 2008-06-16 Dérivés de benzamidazole

Publications (1)

Publication Number Publication Date
MA31466B1 true MA31466B1 (fr) 2010-06-01

Family

ID=40161351

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32454A MA31466B1 (fr) 2007-06-29 2009-12-29 Derives de benzimidazole

Country Status (45)

Country Link
US (2) US8148401B2 (fr)
EP (1) EP2170860B9 (fr)
JP (2) JP4567099B2 (fr)
KR (1) KR101143246B1 (fr)
CN (1) CN101687841B (fr)
AP (1) AP2377A (fr)
AR (1) AR067346A1 (fr)
AU (1) AU2008272641B2 (fr)
BR (1) BRPI0813412B8 (fr)
CA (1) CA2690953C (fr)
CL (1) CL2008001922A1 (fr)
CO (1) CO6160232A2 (fr)
CR (1) CR11150A (fr)
CU (1) CU23847B1 (fr)
CY (2) CY1118650T1 (fr)
DK (1) DK2170860T5 (fr)
DO (1) DOP2009000278A (fr)
EA (1) EA016888B1 (fr)
EC (1) ECSP099803A (fr)
ES (1) ES2609258T3 (fr)
FR (1) FR20C1038I2 (fr)
GE (1) GEP20125702B (fr)
GT (1) GT200900328A (fr)
HN (1) HN2008000974A (fr)
HR (1) HRP20161562T2 (fr)
HU (2) HUE030052T4 (fr)
IL (1) IL202420A (fr)
LT (2) LT2170860T (fr)
MA (1) MA31466B1 (fr)
ME (1) ME00962B (fr)
MY (1) MY148636A (fr)
NI (1) NI200900219A (fr)
NL (1) NL301057I2 (fr)
NO (1) NO2020027I1 (fr)
NZ (1) NZ581889A (fr)
PA (1) PA8785401A1 (fr)
PE (2) PE20121010A1 (fr)
PL (1) PL2170860T3 (fr)
PT (1) PT2170860T (fr)
RS (1) RS55395B9 (fr)
SI (1) SI2170860T1 (fr)
TN (1) TN2009000544A1 (fr)
TW (1) TWI371451B (fr)
UY (1) UY31164A1 (fr)
WO (1) WO2009004427A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2609258T3 (es) * 2007-06-29 2017-04-19 Pfizer Inc. Derivados de bencimidazol
CA2735593C (fr) 2008-09-03 2017-08-15 Repligen Corporation Compositions comprenant des derives d'acide 6-aminohexanoique utilisees comme inhibiteurs de hdac
CN102803246A (zh) * 2009-06-11 2012-11-28 锡耶纳生物技术股份公司 Hedgehog途径拮抗剂及其治疗应用
US8907089B2 (en) 2009-08-26 2014-12-09 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
WO2012052948A1 (fr) 2010-10-20 2012-04-26 Pfizer Inc. Dérivés de pyridine-2 en tant que modulateurs des récepteurs smoothened
JP5452459B2 (ja) 2010-12-16 2014-03-26 株式会社Ｎｔｔドコモ ホーム基地局及びハンドオーバ方法
EP3524324A1 (fr) 2011-02-28 2019-08-14 BioMarin Pharmaceutical Inc. Inhibiteurs de l'histone désacétylase
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2012122370A2 (fr) * 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions et méthodes utiles dans le traitement de maladies
FR2980477B1 (fr) 2011-09-23 2013-10-18 Centre Nat Rech Scient Nouveaux composes modulateurs de la voie de signalisation des proteines hedgehog, leurs formes marquees, et applications
ES2612934T3 (es) * 2011-09-26 2017-05-19 Merck Patent Gmbh Compuestos de piperidin bencilo como antagonista del receptor del ácido lisofosfatídico (LPA)
IN2014DN11205A (fr) 2012-06-20 2015-10-02 Eutropics Pharmaceuticals Inc
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
EP2996689A1 (fr) 2013-04-17 2016-03-23 Albert-Ludwigs-Universität Freiburg Composés destinés à être utilisés comme inhibiteurs de bromodomaine
WO2015017788A1 (fr) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Méthode permettant de prédire la sensibilité d'un cancer
GB2519344A (en) * 2013-10-18 2015-04-22 Redx Pharma Ltd Compounds
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
HUE048664T2 (hu) * 2015-04-24 2020-07-28 Pfizer 1-((2R,4R)-2-(1H-benzo[D]imidazol-2-il)-l-metilpiperidin-4-il)-3-(4-cianofenil)-karbamid-maleát kristályformái
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
JP7792189B2 (ja) * 2019-03-29 2025-12-25 デクセリアルズ株式会社 接着剤組成物
HRP20240302T1 (hr) 2020-01-28 2024-05-10 Assia Chemical Industries Ltd Postupci za pripremu glasdegiba i njegove soli i krutih oblika glasdegib maleata i postupak za njihovu pripremu
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
EP4126237B1 (fr) 2020-03-26 2024-04-10 LEK Pharmaceuticals d.d. Forme dimaléate de 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-méthylpipéridine?-4-yl)-3-(4-cyanophényl)urée
WO2021261601A1 (fr) 2020-06-26 2021-12-30 ラクオリア創薬株式会社 Méthode de sélection d'un patient cancéreux pour lequel une polythérapie d'un rétinoïde et d'un agent de traitement du cancer sera efficace, et médicament combiné d'un rétinoïde et d'un agent de traitement du cancer
WO2023002362A1 (fr) 2021-07-22 2023-01-26 Pfizer Inc. Traitement d'une malignité hématologique

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003011219A2 (fr) 2001-07-27 2003-02-13 Curis, Inc. Mediateurs des voies de signalisation hedgehog, compositions associees et utilisations de ces dernieres
DK1499607T3 (da) 2001-12-04 2006-04-18 Actelion Pharmaceuticals Ltd 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-quinoliner som urotensin II-receptorantagonister
TW200304820A (en) 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
US7582761B2 (en) 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005042495A1 (fr) 2003-10-21 2005-05-12 Imclone Systems Incorporated Composes de (benzimidazol-2-yl)-phenyl-phenyl-uree et procedes d'inhibition de l'activite de l'heparanase
WO2005042497A2 (fr) 2003-10-28 2005-05-12 Vertex Pharmaceuticals, Incorporated Benzimidazoles convenant comme modulateurs des canaux ioniques
CA2587489C (fr) * 2004-11-03 2013-12-31 Curis, Inc. Mediateurs de chemins de signalisation hedgehog, compositions et utilisations liees a ceux-ci
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
WO2006124780A2 (fr) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibiteurs de la b-raf kinase
WO2008064830A1 (fr) 2006-11-27 2008-06-05 Ucb Pharma, S.A. Dérivés bicycliques et hétérobicycliques, leurs procédés de fabrication et leurs utilisations pharmaceutiques
EP2121626A1 (fr) 2006-12-15 2009-11-25 Pfizer Products Inc. Dérivés du benzamidazole
ES2609258T3 (es) 2007-06-29 2017-04-19 Pfizer Inc. Derivados de bencimidazol
US20120094974A1 (en) 2008-06-17 2012-04-19 Wei Chen Smoothened receptor modulators
KR101354763B1 (ko) 2008-08-25 2014-01-22 아이알엠 엘엘씨 헷지호그 경로 조절제

Also Published As

Publication number Publication date
HRP20161562T2 (hr) 2017-04-21
LTC2170860I2 (lt) 2022-03-10
FR20C1038I2 (fr) 2021-08-13
GT200900328A (es) 2011-08-29
EA200971104A1 (ru) 2010-06-30
CN101687841B (zh) 2013-07-10
DOP2009000278A (es) 2009-12-31
US20090005416A1 (en) 2009-01-01
BRPI0813412B1 (pt) 2020-01-21
CO6160232A2 (es) 2010-05-20
ECSP099803A (es) 2010-01-29
IL202420A0 (en) 2010-06-30
NL301057I2 (nl) 2020-09-10
TWI371451B (en) 2012-09-01
KR20100028120A (ko) 2010-03-11
TW200911792A (en) 2009-03-16
CN101687841A (zh) 2010-03-31
IL202420A (en) 2014-05-28
AR067346A1 (es) 2009-10-07
EP2170860B1 (fr) 2016-11-02
AP2377A (en) 2012-03-07
CU23847B1 (es) 2012-10-15
RS55395B9 (sr) 2020-01-31
UY31164A1 (es) 2009-01-30
PT2170860T (pt) 2017-01-04
HUE030052T2 (hu) 2017-04-28
MY148636A (en) 2013-05-15
SI2170860T1 (sl) 2017-01-31
US20120157495A1 (en) 2012-06-21
BRPI0813412A2 (pt) 2014-12-30
PE20121010A1 (es) 2012-08-06
EA016888B1 (ru) 2012-08-30
JP4567099B2 (ja) 2010-10-20
CY1118650T1 (el) 2017-07-12
LTPA2020528I1 (lt) 2020-09-25
DK2170860T5 (en) 2017-03-20
DK2170860T3 (en) 2017-01-09
AU2008272641A1 (en) 2009-01-08
PA8785401A1 (es) 2009-01-23
US8148401B2 (en) 2012-04-03
CA2690953C (fr) 2012-10-02
CU20090225A7 (es) 2012-02-15
FR20C1038I1 (fr) 2020-10-02
ME00962B (fr) 2012-06-20
HK1139658A1 (en) 2010-09-24
CY2020028I1 (el) 2020-11-25
RS55395B1 (sr) 2017-04-28
CR11150A (es) 2010-02-08
NO2020027I1 (no) 2020-08-11
WO2009004427A2 (fr) 2009-01-08
CA2690953A1 (fr) 2009-01-08
BRPI0813412B8 (pt) 2021-05-25
CL2008001922A1 (es) 2009-01-02
TN2009000544A1 (fr) 2011-03-31
CY2020028I2 (el) 2020-11-25
AP2009005089A0 (en) 2009-12-31
EP2170860B9 (fr) 2017-02-22
HUS2000031I1 (hu) 2020-09-28
HRP20161562T1 (hr) 2016-12-30
NZ581889A (en) 2011-05-27
PL2170860T3 (pl) 2017-05-31
ES2609258T3 (es) 2017-04-19
JP2010280693A (ja) 2010-12-16
LT2170860T (lt) 2017-01-10
KR101143246B1 (ko) 2012-05-18
GEP20125702B (en) 2012-12-10
NL301057I1 (nl) 2020-07-22
EP2170860A2 (fr) 2010-04-07
NI200900219A (es) 2010-03-11
PE20090772A1 (es) 2009-06-24
US8431597B2 (en) 2013-04-30
AU2008272641B2 (en) 2013-08-29
WO2009004427A3 (fr) 2009-06-04
HN2008000974A (es) 2011-01-24
JP2010531869A (ja) 2010-09-30
HUE030052T4 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
MA31466B1 (fr) Derives de benzimidazole
TN2009000428A1 (fr) Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA29926B1 (fr) Derives de pyrazine
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA28747B1 (fr) Dérivés de pyridine
MA31419B1 (fr) Derives de pyridine
MA30352B1 (fr) Pyridine [3,4-b] pyrazinones
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
CY1110504T1 (el) Αναστολεις κινασης πρωτεϊνης
MA30781B1 (fr) Inhibiteur de kinase
MA29909B1 (fr) Derives de pyridazine
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
BR0313743A (pt) Benzimidazol quinolinonas e usos destas
MA31373B1 (fr) Composes amino-heterocycliques
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
MA30411B1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase